AstraZeneca plc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? AstraZeneca plc trades at $157.96 (market cap $248.14B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $428.15 (market cap $1.93T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 7.8× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | TSM | |
|---|---|---|
Market Cap | $248.14B | $1.93T |
Sector | Health | Technology |
52-Week High | $209.48 | $477.57 |
52-Week Low | $147.06 | $227.33 |
Enterprise Value | $275.41B | $1.85T |
Dividend Yield | 2.01% | 0.9% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →